(Q39426985)

11 September 2017

title

Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group (English)

1 reference

11 September 2017

1 reference

Hans-Christoph Diener

4

object named as

H C Diener

1 reference

11 September 2017

H Havanka

1

1 reference

11 September 2017

C Dahlöf

2

1 reference

11 September 2017

P H Pop

3

1 reference

11 September 2017

P Winter

5

1 reference

11 September 2017

H Whitehouse

6

1 reference

11 September 2017

H Hassani

7

1 reference

11 September 2017

publication date

1 August 2000

1 reference

11 September 2017

published in

Clinical Therapeutics

1 reference

11 September 2017

volume

22

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

970-980

1 reference

Measuring the functional status and well-being of patients with migraine headache.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980068-5

7 January 2021

Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980068-5

7 January 2021

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980068-5

7 January 2021

Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980068-5

7 January 2021

A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980068-5

7 January 2021

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980068-5

7 January 2021

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980068-5

7 January 2021

10.1016/S0149-2918(00)80068-5

Identifiers

DOI

1 reference

11 September 2017

1 reference